Form 4: AbCellera Biologics Director Andrew Lo Acquires Shares Through Option Exercise

Director Andrew Lo reports acquisition of AbCellera Biologics shares through the exercise of share options.

Summary

• On June 21, 2024, Andrew Lo, a director of AbCellera Biologics Inc., acquired 163,934 common shares through the exercise of share options at a price of $2.94.
• Following the transaction, Lo directly owns 302,490 common shares.
• The share options were granted on June 12, 2025, and expire on June 21, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of a director exercising stock options. While insider buying can be seen as positive, it's a routine transaction.

Positives

• A director exercising options can be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The details provided, such as the number of shares, transaction date, and exercise price, are consistent with the information required in such filings.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates a director's confidence in the company.

Key Dates